Let's look at the good parts !

Anonymous

Guest
Finally, we are getting the very past due dividend. The figures will be announced July 29, a Friday. It will be based on 20% of the net income, which last 1/4 came to about 27 cents a share each 1/4. That's about $1.08 a year. It sure beats looking at the the stock going no where. This move should stabilize and improve the holding time of the shareholder, as well as attract those that like reliability which a dividend provides. People who like dividends tend to stay a lot longer than other investors.

Kevin will retire on his 65 birthday which is just a little more than a year and a half away.

The back log of superdrugs is not very impressive but hopefully the new head will freshen the pipeline with serious, in depth studies and potential money making abilities of novel therapies.
 












When is Sean taking over Roger's position as head of R&D and Mike S. becoming the new CMO and head of development? it should be happening pretty soon I heard.

Our main concern should be who will take over Kevin Sharer's job? We need someone who has a excellent working background in biotech or pharma, as well as being a responsive manager, with the shareholder interest at heart.

That person will be able to make whatever management changes are necessary at the lower levels. With a fresh management team, Amgen will have the chance of a being a new world, again.
 






Our main concern should be who will take over Kevin Sharer's job? We need someone who has a excellent working background in biotech or pharma, as well as being a responsive manager, with the shareholder interest at heart.

That person will be able to make whatever management changes are necessary at the lower levels. With a fresh management team, Amgen will have the chance of a being a new world, again.

First things first. Clean out the brain-dead BOD that watched KS to do anything he wanted (and I mean anything) and allowed him to name his own compensation for the last decade.